Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model

Gastroenterology

Volumn 123, Issue 6, 2002, Pages 1865-1876

  Van Montfrans, Catherine ^a   Rodriguez Pena, Maria Sol ^a   Pronk, Inge ^a   Ten Kate, Fiebo J W ^a   Te Velde, Anje A ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; RETROVIRUS VECTOR; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; GENETIC ENGINEERING; HELPER CELL; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; SCID MOUSE;

EID: 0036893171     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.37067     Document Type: Article

References (52)

1. Fiocchi C.Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Fiocchi C. From immune activation to gut tissue injury: The pieces of the puzzle are coming together. Gastroenterology 1999;117:1238-1241.
3. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspasedependent pathway. Gastroenterology 2001;121:1145-1157.
4. ten Hove T, van Montfrans C, Peppelenbosch M, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-211.
5. Marth T, Zeitz M, Ludviksson BR, Strober W, Kelsall BL. Extinction of IL-12 signaling promotes Fas-mediated apoptosis of antigenspecific T cells. J Immunol 1999;162:7233-7240.
6. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-1088.
7. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-588.
8. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-769.
9. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
10. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
11. Toms C, Powrie F. Control of intestinal inflammation by regulatory T cells. Microbes Infect 2001;3:929-935.
12. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer S, Kilian A, Cohard M, LeBeaut A, Feagan B, and the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119:1473-1482.
13. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams NC, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJH, Koningsberger JC, Cohard M, Lebaut A, Hanauer SB, and the Crohn's Disease IL-10 Cooperative Study Group. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000;119:1461-1472.
14. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJH, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000;165:2783-2789.
15. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJH, Schreiber S, Gregor M, Rutgeerts P, Gasche C, Koningsberger JC, Kuhn I, Cohard M, Lebeaut A, Grint P, Weiss G. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 2002;50:191-195.
16. Asseman C, Powrie F. Interleukin 10 is a growth factor for a population of regulatory T cells. Gut 1998;42:157-158.
17. Chen LZ, Hochwald GM, Huang C, Dakin G, Tao H, Cheng C, Simmons WJ, Dranoff G, Thorbecke GJ. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-β1. Proc Natl Acad Sci U S A 1998;95:12516-12521.
18. Setoguchi K, Misaki Y, Araki Y, Fujio K, Kawahata K, Kitamura T, Yamamoto K. Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J Immunol 2000;165:5980-5986.
19. Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, Bachmann MH, Contag CH, Fathman CG. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin invest 2001;107:1293-1301.
20. Heemskerk MHM, Hooijberg E, Ruizendaal JJ, van der Weide MMC, Kueter E, Bakker AQ, Schumacher TNM, Spits H. Enrichment of antigen-specific T cell response by retrovirally transduced human dendritic cells. Cell Immunol 1999;195:10-17.
21. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996;7:1405-1413.
22. Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, de Vries JE, Roncarolo MG, Mosmann TR, Moore KW. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 1991;88:1172-1176.
23. Powrie F, Read S. Induction of inflammatory bowel disease in immunodeficient mice by depletion of regulatory T cells. In: Coico R, ed. Current Protocols in Immunology. Volume 4. New York: John Wiley & Sons, Inc., 1999:15.13.1-15.13.10.
24. Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, Drillenburg P, van Deventer SJ, Chvatchko Y, Te Velde AA. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001;121:1372-1379.
25. van Montfrans C, Hooijberg E, Spits H, te Velde AA, van Deventer SJH. Therapeutic potential of genetically modified T-lymphocytes in Crohn's disease (abstr). Gastroenterology 2000;118:A873.
26. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-1471.
27. Hagenbaugh A, Sharma S, Dubinett SM, Wei SHY, Aranda R, Cheroutre H, Fowell DJ, Binder S, Tsao B, Locksley RM, Moore KW, Kronenberg M. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997;185:2101-2110.
28. Rudolphi A, Boll G, Poulsen SS, Claesson MH, Reimann J. Guthoming CD4+ T cell receptor α β + T cells in the pathogenesis of murine inflammatory bowel disease. Eur J Immunol 1994;24:2803-2812.
29. high T cells to SCID recipients. J Immunol 1997;158:3464-3473.
30. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995;85:842-851.
31. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993;11:165-190.
32. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
33. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-274.
34. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993;150:4754-4765.
35. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993;81:2964-2971.
36. Pannell D, Ellis J. Silencing of gene expression: Implications for design of retrovirus vectors. Rev Med Virol 2001;11:205-217.
37. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: Implications for gene therapy. Gene Ther 1999;6:1305-1312.
38. Kang E, Giri N, Wu T, Sellers S, Kirby M, Hanazono Y, Tisdale J, Dunbar CE. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther 2001;12:1663-1672.
39. Barrette S, Douglas JL, Seidel NE, Bodine DM. Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to Moloney murine leukemia virus-based vectors. Blood 2000;96:3385-3391.
40. Donahue RE, Wersto RP, Allay JA, Agricola BA, Metzger ME, Nienhuis AW, Persons DA, Sorrentino BP. High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells. Blood. 2000;95:445-452.
41. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey V, Pantaleo G, Demarest JF, Carter C, Wannebo C, Yannelli JR, Rosenberg SA, Lane HC. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995;1:330-336.
42. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
43. Ribbons KA, Thompson JH, Liu XP, Pennline K, Clark DA, Miller MJS. Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur J Pharmacol 1997;323:245-254.
44. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-938.
45. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 2000;46:344-349.
46. Annacker O, Burlen-Defranoux O, Pimenta-Araujo R, Cumano A, Bandeira A. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. J Immunol 2000;164:3573-3580.
47. Wirtz S, Galle PR, Neurath MF. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut 1999;44:800-807.
48. Lindsay JO, Ciesielski CJ, Brennan FN. Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response (abstr). Gastroenterology 2001;120:A687.
49. Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum GeneTher 2000;11:1731-1741.
50. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
51. high expression by gut derived T lymphocytes in Crohn's disease and ulcerative colitis (abstr). Gastroenterology 2001;120:A526.
52. Meresse B, Rutgeerts P, Malchow H, Dubucquoi S, Dessaint JP, Cohard M, Colombel JF, Desreumaux P. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut 2002;50:25-28.